Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
1.320
+0.080 (6.45%)
Apr 1, 2025, 4:00 PM EDT - Market closed
Cellectis Revenue
In the year 2024, Cellectis had annual revenue of $49.22M with 435.37% growth. Cellectis had revenue of $15.17M in the quarter ending December 31, 2024, with 662.06% growth.
Revenue (ttm)
$49.22M
Revenue Growth
+435.37%
P/S Ratio
1.89
Revenue / Employee
$221,698
Employees
222
Market Cap
93.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 49.22M | 40.02M | 435.37% |
| Dec 31, 2023 | 9.19M | -16.53M | -64.26% |
| Dec 31, 2022 | 25.72M | -12.87M | -33.35% |
| Dec 31, 2021 | 38.60M | -20.97M | -35.20% |
| Dec 31, 2020 | 59.56M | 36.57M | 159.09% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
CLLS News
- 18 days ago - Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update - GlobeNewsWire
- 24 days ago - Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025 - GlobeNewsWire
- 5 weeks ago - Cellectis Presents ‘Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 - GlobeNewsWire
- 3 months ago - Cellectis: Poised To Start Answering Questions In 2025 - Seeking Alpha
- 3 months ago - Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB) - GlobeNewsWire
- 5 months ago - Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting - GlobeNewsWire
- 5 months ago - Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript - Seeking Alpha